Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 5/20 | 0.77 |
| ▸ | ADORA2A known ✓ | P29274 | 2/20 | 0.77 |
| ▸ | ADORA2B known ✓ | P29275 | 2/20 | 0.77 |
| ▸ | ADORA1 known ✓ | P30542 | 2/20 | 0.77 |
| ▸ | DPP4 | P27487 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.77 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.77 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.77 |
| ▸ | GAPDH | P04406 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | STAT6 | P42226 | 1/20 | 0.77 |
| ▸ | PI4KA | P42356 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.77 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.77 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.77 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.77 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL5034955 | 1.00 | ADORA3 (0.77) | ADORA3ADORA2AADORA2BADORA1DPP4 | |
| Adenosine SCHEMBL11061671 | 0.95 | ADORA3 (0.85) | ADORA3ADORA2AADORA2BADORA1DPP4 | |
| Adenosine SCHEMBL11061662 | 0.95 | ADORA3 (0.85) | ADORA3ADORA2AADORA2BADORA1DPP4 | |
| Adenosine SCHEMBL4396199 | 0.94 | ADORA3 (0.87) | ADORA3ADORA2AADORA2BADORA1DPP4 | |
| Adenosine SCHEMBL4401875 | 0.94 | ADORA3 (0.87) | ADORA3ADORA2AADORA2BADORA1DPP4 | |
| Adenosine SCHEMBL6749752 | 0.94 | ADORA3 (0.87) | ADORA3ADORA2AADORA2BADORA1DPP4 | |
| Adenosine SCHEMBL4138547 | 0.91 | ADORA3 (0.89) | ADORA3ADORA2AADORA2BADORA1DPP4 | |
| Adenosine SCHEMBL5708451 | 0.90 | ADORA3 (0.81) | ADORA3ADORA2AADORA2BADORA1DPP4 | |
| Adenosine SCHEMBL5703561 | 0.90 | ADORA3 (0.81) | ADORA3ADORA2AADORA2BADORA1DPP4 | |
| Adenosine SCHEMBL27728504 | 0.90 | ADORA3 (0.80) | ADORA3ADORA2AADORA2BADORA1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262214-A1 | Synthesis of 2-Substituted Adenosines | CAMBRIDGE BIOTECHNOLOGY LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1697393-A1 | IMPROVED SYNTHESIS OF 2-SUBSTITUTED ADENOSINES | BIOVITRUM AB (SE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005054269-A1 | IMPROVED SYNTHESIS OF 2-SUBSTITUTED ADENOSINES | BIOVITRUM AB (SE) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262214-A1 | Synthesis of 2-Substituted Adenosines | ADORA3, ADORA1, ADORA2A | ADORA3 1/4885ADORA2A 3/4885ADORA2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.